Aurora Cannabis (ACB) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Aurora Cannabis (ACB) over the past year, gaining 25.6% versus a loss of 27.4%. Over five years, EOLS leads with a +1.7% price change compared with -93.7% for ACB. Evolus is the larger company by market cap ($515.2 million vs $280.5 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACB | EOLS |
|---|---|---|
| Share price | $4.43 | $7.80 |
| Market cap | $280.46M | $515.19M |
| 1-day change | -0.67% | +0.78% |
| YTD return | +4.98% | +17.29% |
| 1-year return | -27.38% | +25.60% |
| 5-year return | -93.70% | +1.69% |
| Forward P/E | — | 26.67 |
| EPS (TTM) | $-0.61 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.67 | $9.31 |
| 52-week low | $2.56 | $3.86 |
| Distance from 52-week high | -33.53% | -16.22% |
| Analyst consensus | buy | none |
| Avg. price target upside | — | +92.31% |
| Average volume | 1.36M | 900.79K |
| Shares outstanding | 63.31M | 66.05M |
| Employees | 1,028 | 353 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed ACB by 53.0 percentage points over the past year.
About Aurora Cannabis
ACB stock →Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,028 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
ACB vs EOLS FAQ
Which is bigger, Aurora Cannabis or Evolus?
Evolus (EOLS) is larger, with a market capitalization of $515.19M compared with $280.46M for Aurora Cannabis (ACB).
Which stock has performed better over the past year, ACB or EOLS?
EOLS returned +25.60% over the past 12 months, compared with -27.38% for ACB (price return, excluding dividends). Past performance does not predict future results.
Are Aurora Cannabis and Evolus in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.